nach oben

Geriatrie-Report

Erschienen in:

04.09.2018 | Vorhofflimmern | Zertifizierte Fortbildung

Der geriatrische Patient mit Vorhofflimmern

Orale Antikoagulation: Was Sie bei Senioren beachten sollten

verfasst von: Privatdozent Dr. med. Philipp Bahrmann, MHBA, FESC

Erschienen in: Geriatrie-Report | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei betagten Patienten mit Vorhofflimmern ist die Antikoagulation eine Gratwanderung: Einerseits ist im Alter die Schlaganfallgefahr erhöht, gleichzeitig steigt aber auch das Risiko für schwere Blutungen. Beachtet der Arzt bei der Wahl des Präparats und der Dosierung Faktoren wie Nierenfunktion, Begleitmedikation, Therapieadhärenz und Sturzrisiko, überwiegt in vielen Fällen der Nutzen einer Antikoagulationstherapie.

Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E. Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace 2013;15:1436–44.CrossRefPubMed

Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15:486–93.CrossRefPubMed

Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008;92:17–40.CrossRefPubMedPubMedCentral

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5.CrossRefPubMed

Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760–4.CrossRefPubMed

Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429.CrossRefPubMed

Camm A, Lip G, Atar D, et al. 2012 Focused Update of the ESC Guidelines on the Management of Atrial Fibrillation. Eur Heart J 2012;33:2719–47.CrossRefPubMed

Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. Agency for Healthcare Research and Quality (US); August 2013. Report No.: 13-EHC113-EF. AHRQ Comparative Effectiveness Reviews. Accessed on 9 November 2014.

Schwabe U, Paffrath D. Arzneiverordnungs-Report 2014: Aktuelle Daten, Kosten, Trends und Kommentare. Springer Verlag, Auflage September 2014.CrossRef

10.

Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423–34.CrossRefPubMedPubMedCentral

11.

Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568–76.CrossRefPubMed

12.

De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087–107.CrossRefPubMed

13.

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011;365:883–91.CrossRefPubMed

14.

Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.CrossRefPubMed

15.

Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981–92.CrossRefPubMed

16.

January CT, Wann S, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Managment of Patients With Atrial Fibrillation: Executive Summary. Circulation 2014;130:2071–104.CrossRefPubMed

17.

Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87 Suppl 1:S141–5.CrossRefPubMed

18.

Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014;111:833–41.CrossRefPubMed

19.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.CrossRefPubMed

20.

Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015;132:194–204.CrossRefPubMedPubMedCentral

21.

Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J. New oral anticoagulants for prophylaxis of stroke. Z Gerontol Geriatr 2016;49:216–26.CrossRefPubMed

22.

Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015;36:3238–49.PubMed

23.

Boltz MM, Podany AB, Hollenbeak CS, Armen SB. Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy. Injury;46:1765–71.

24.

Suárez Fernández C, Formiga F, Camafort M, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovascular Disorders 2015;15:143.CrossRefPubMedPubMedCentral

25.

Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003;48:133–43.CrossRefPubMed

26.

Lu Y, Won KA, Nelson BJ, Qi D, Rausch DJ, Asinger RW. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm 2008;65:947–52.CrossRefPubMed

27.

Mueller E, Kirch W. Phenprocoumon (Marcumar®): gefährliche Interaktionen. Arzneiverordnung in der Praxis 2009;36:141–43.

28.

De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59:1413–25.CrossRefPubMed

29.

Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001;51:615–22.CrossRefPubMedPubMedCentral

30.

World Health Organisation. Adherence to long-term therapies: Evidence for action. Geneva, 2003. Internet: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed on 9 November 2014.

31.

Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–35.CrossRef

32.

Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med 2014;160:441–50.CrossRefPubMed

33.

Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011;9:11–23.CrossRefPubMedPubMedCentral

34.

Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500–6.CrossRefPubMed

35.

Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540–50.CrossRefPubMed

36.

Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev 2014;4:CD007768.

37.

Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008:CD000011.

38.

Mansoor SM, Krass I, Aslani P. Multiprofessional interventions to improve patient adherence to cardiovascular medications. J Cardiovasc Pharmacol Ther 2013;18:19–30.CrossRefPubMed

39.

Nikolaus T, Kruse W, Bach M, Specht-Leible N, Oster P, Schlierf G. Elderly patients’ problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol 1996;49:255–9.CrossRefPubMed

40.

Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278–85.CrossRefPubMed

41.

Morrill AM, Ge D, Willett KC. Dosing of Target-Specific Oral Anticoagulants in Special Populations. Annals of Pharmacotherapy 2015;49:1031–45.CrossRef

42.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.CrossRefPubMed

43.

Shoker A, Hossain MA, Koru-Sengul T, Raju DL, Cockcroft D. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 2006;66:89–97.CrossRefPubMed

44.

Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–54.CrossRefPubMed

45.

Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998;51:1357–65.CrossRefPubMed

46.

Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:223–42.CrossRefPubMed

47.

Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269–367.CrossRefPubMed

48.

Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009;38:156–62.CrossRefPubMed

49.

Chronopoulos A, Cruz DN, Ronco C. Hospital-acquired acute kidney injury in the elderly. Nat Rev Nephrol 2010;6:141–9.CrossRefPubMed

50.

Deal EN, Pope H, Ross W. Apixaban Use Among Patients With Severe Renal Impairment. Annals of Pharmacotherapy 2014;48:1667.CrossRef

51.

Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130:138–46.CrossRefPubMed

52.

Berthold HK. New oral anticoagulants for the prevention of stroke. Z Gerontol Geriatr 2012;45:498–504.CrossRefPubMed

53.

Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the Risk of Bleeding with NOACs in the Elderly. Drugs Aging 2016:1–10.

54.

Kooiman J, van de Peppel WR, van der Meer FJM, Huisman MV. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011;9:1652–3.CrossRefPubMed

55.

Jönsson KM, Wieloch M, Sterner G, et al. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: A subgroup analysis from the AURICULA registry in Sweden. Thromb Res;128:341–5.

56.

Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821–30.CrossRefPubMed

57.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369:2093–104.CrossRefPubMed

58.

Bahrmann P, Christ M. Anticoagulation in geriatric patients with atrial fibrillation: With what and for whom no more? Herz 2018;43(3):214–221.CrossRefPubMed

Titel: Der geriatrische Patient mit Vorhofflimmern
Orale Antikoagulation: Was Sie bei Senioren beachten sollten
verfasst von: Privatdozent Dr. med. Philipp Bahrmann, MHBA, FESC
Publikationsdatum: 04.09.2018
Verlag: Springer Medizin
Schlagwörter: Vorhofflimmern
Direkte orale Antikoagulanzien
Direkte orale Antikoagulanzien
Dabigatran
Apixaban
Edoxaban
Erschienen in: Geriatrie-Report / Ausgabe 3/2018
Print ISSN: 1862-5363
Elektronische ISSN: 2520-8950
DOI: https://doi.org/10.1007/s42090-018-0058-6

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Neuer Impfstoff schützt vor Zoster und Postzoster-Neuralgie

PEG im Alter — Wann ist sie indiziert?

Tipps für die Influenzaimpfung bei Senioren

Typ-2-Diabetes: Neue Fixkombination mit SGLT-2- und DPP-4-Hemmer auf dem Markt

Therapie des Typ-2-Diabetes sollte auch vaskulären Schutz bieten

Ältere Patienten mit Depression haben ein deutlich erhöhtes Polypharmazierisiko